標(biāo)題: Titlebook: Renal Cell Carcinoma; Molecular Targets an Ronald M. Bukowski,Robert A. Figlin,Robert J. Motz Book 2015Latest edition Springer Science+Busi [打印本頁(yè)] 作者: purulent 時(shí)間: 2025-3-21 18:15
書目名稱Renal Cell Carcinoma影響因子(影響力)
作者: Panacea 時(shí)間: 2025-3-22 00:00
978-1-4939-5063-8Springer Science+Business Media New York 2015作者: 阻塞 時(shí)間: 2025-3-22 02:20
http://image.papertrans.cn/r/image/826986.jpg作者: Fraudulent 時(shí)間: 2025-3-22 07:23
Targeted Therapy for Metastatic Renal Cell Carcinoma: Introduction,ular targets identified in RCC. The ongoing evolution of this new treatment paradigm and development of multiple targeted agents with significant clinical activity in patients with advanced clear-cell carcinoma prompted this undertaking. Additionally, recent data investigating the molecular effects 作者: 鬼魂 時(shí)間: 2025-3-22 10:40
Renal Cell Carcinoma: Pathologic and Molecular Assessment of Targets,dered lipomas, originated in the neoplastic transformation of adrenal cortical residues into renal cortical. One year later, he confirmed his theory when he found ectopic adrenal cortex in the renal cortex. This theory was readily opposed by Sudek, who favored a renal tubular origin. The controversy作者: 過(guò)多 時(shí)間: 2025-3-22 12:58 作者: 個(gè)人長(zhǎng)篇演說(shuō) 時(shí)間: 2025-3-22 19:22 作者: Champion 時(shí)間: 2025-3-23 00:19
PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex, cancer biomarkers. Also, they have triggered intensive efforts in basic science laboratories to elucidate the biological function behind each enigmatic gene, with a view toward refining paradigms that more accurately reflect ccRCC formation and disease progression, and for developing better strateg作者: 鋼盔 時(shí)間: 2025-3-23 02:21
Sporadic RCC: Abnormalities in Histone-Modifying Genes,Oncol Hematol 88(1):42–56, 2013). The elucidation of VHL function and mTOR pathway activation led to the discovery of VEGF and mTOR inhibitors for RCC treatment. Recently, secondary mutations identified in histone-modifying enzymes suggest that chromatin remodeling and alterations of histone modific作者: 刺耳 時(shí)間: 2025-3-23 08:12 作者: GLUE 時(shí)間: 2025-3-23 12:40 作者: tenuous 時(shí)間: 2025-3-23 17:38
Second-Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status, the treatment of mRCC in patients with good/intermediate prognosis, in treatment-na?ve patients, and/or in patients refractory to cytokines (Pick and Nystrom, Clin Ther 34:511–520, 2012). Its use in the adjuvant setting is also currently under investigation.作者: DECRY 時(shí)間: 2025-3-23 20:53 作者: 圖畫文字 時(shí)間: 2025-3-24 01:43
PI3-kinase, Akt, and mTOR Inhibitors in RCC,ikely to derive significant clinical benefit and (b) developing novel agents with broader clinical activity. In this chapter, we will review the molecular biology of this pathway, the clinical efficacy of approved agents, efforts to identify predictive biomarkers of response, and novel therapeutic s作者: MIRE 時(shí)間: 2025-3-24 04:19 作者: Phenothiazines 時(shí)間: 2025-3-24 08:53 作者: ARC 時(shí)間: 2025-3-24 14:01 作者: jocular 時(shí)間: 2025-3-24 18:49 作者: Antagonist 時(shí)間: 2025-3-24 22:06
Egbert Oosterwijk Ph.D.,Otto C. Boerman Ph.D.,Jeannette C. Oosterwijk-Wakka B.Sc.,Wim J. Oyen M.D., received an enormous amount of research in the last four decades, with lots of publications of articles and textbooks in the field. There are, however, concepts in the numerical machinery for treating the pressure–velocity coupling which takes time to mature for reaching a good deep understanding. T作者: 充足 時(shí)間: 2025-3-24 23:20
Sarathi Kalra M.D.,Eric Jonasch M.D.his knowledge to curvilinear and unstructured grids. As such, the book contains material for introductory courses on CFD for under and graduate students, as well as for more advanced students and researchers..978-3-031-18237-2978-3-031-18235-8Series ISSN 0926-5112 Series E-ISSN 2215-0056 作者: Keshan-disease 時(shí)間: 2025-3-25 06:55 作者: 執(zhí) 時(shí)間: 2025-3-25 10:11
James W. Mier M.D.,Rupal S. Bhatt M.D., Ph.D.,David J. Panka Ph.D.,Michael B. Atkins M.D.s of these natural disasters, but also the locations of large concealed natural resources in the deep Earth. For this reason, geoscientists must study the processes, rules and laws, by which the Earth system operates, instead of simply describing and observing geoscience phenomena. Specifically, geo作者: Lobotomy 時(shí)間: 2025-3-25 15:09
C. Lance Cowey M.D.,Thomas E. Hutson D.O., Pharm.D., F.A.C.P. in pore-fluid flow can cause a considerable change in the chemical-species concentration within the porous medium (Steefel and Lasaga 1990, 1994, Yeh and Tripathi 1991, Raffensperger and Garven 1995, Shafter et al. 1998a, b, Xu et al. 1999, 2004, Ormond and Ortoleva 2000, Chen and Liu 2002, Zhao et作者: 舊石器時(shí)代 時(shí)間: 2025-3-25 18:38 作者: ineluctable 時(shí)間: 2025-3-25 21:53
Daniel C. Cho M.D.,James W. Mier M.D. mathematical framework to describe and unify most numerical methods in common use for solving the partial differential equations governing the physics of fluid flow. This approach originated with the first aut978-3-642-07484-4978-3-662-04654-8Series ISSN 1434-8322 Series E-ISSN 2198-2589 作者: meretricious 時(shí)間: 2025-3-26 02:32
Ronald M. Bukowski M.D.,Robert A. Figlin M.D., F.A.C.P.,Robert J. Motzer M.D.作者: 松軟無(wú)力 時(shí)間: 2025-3-26 07:49
Stephen M. Keefe M.D.,W. Kimryn Rathmell M.D., Ph.D.,Katherine L. Nathanson M.D.作者: 漂浮 時(shí)間: 2025-3-26 08:44 作者: saturated-fat 時(shí)間: 2025-3-26 15:59 作者: 飛鏢 時(shí)間: 2025-3-26 18:48 作者: chalice 時(shí)間: 2025-3-27 01:00 作者: Working-Memory 時(shí)間: 2025-3-27 05:07
James M. G. Larkin Ph.D., F.R.C.P.,Martin E. Gore Ph.D., F.R.C.P.作者: FAWN 時(shí)間: 2025-3-27 08:02 作者: JADED 時(shí)間: 2025-3-27 10:26
Hui Zhu M.D., Ph.D.,Brian I. Rini M.D., F.A.C.P.lved in finite-volume schemes. The equations are then recast into divergence form, which is natural for finite-difference schemes. The Euler and Navier—Stokes equations are briefly discussed in this chapter. The main focus, though, will be on representative model equations, in particular, the convec作者: figure 時(shí)間: 2025-3-27 14:33 作者: groggy 時(shí)間: 2025-3-27 21:08 作者: 寵愛(ài) 時(shí)間: 2025-3-28 01:13 作者: 乏味 時(shí)間: 2025-3-28 03:56 作者: 狂熱語(yǔ)言 時(shí)間: 2025-3-28 06:38
Fabiola Cecchi Ph.D.,Young H. Lee Ph.D.,Benedetta Peruzzi Ph.D.,Jean-Baptiste Lattouf M.D.,Donald P.lpful content for the development of numerical methods for f. .This book presents the developments of the finite volume method applied to fluid flows, starting from the foundations of the method and reaching the latest approaches using unstructured grids. It helps students learn progressively, creat作者: 馬賽克 時(shí)間: 2025-3-28 10:42 作者: Pseudoephedrine 時(shí)間: 2025-3-28 14:44 作者: 貴族 時(shí)間: 2025-3-28 19:53 作者: Cabinet 時(shí)間: 2025-3-29 02:01
Book 2015Latest editionusing on the novel targets that have been discovered in epithelial renal tumors..Comprehensive and authoritative, .Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition. is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.?.作者: faucet 時(shí)間: 2025-3-29 03:21
sive and authoritative, .Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition. is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.?.978-1-4939-5063-8978-1-4939-1622-1作者: Madrigal 時(shí)間: 2025-3-29 09:29
EGFR and HER2: Relevance in Renal Cell Carcinoma,is chapter and have been studied in renal cell carcinoma are cetuximab, panitumumab, gefitinib, erlotinib, and lapatinib. These agents have failed to demonstrate consistent clinical benefit in patients with advanced renal cell carcinoma and are currently not considered standard treatment in this disease.作者: 背心 時(shí)間: 2025-3-29 11:39
ing field of renal cell carcinoma personalized medicine, wit??.?The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributor作者: 移植 時(shí)間: 2025-3-29 17:37 作者: 牙齒 時(shí)間: 2025-3-29 22:44 作者: WAG 時(shí)間: 2025-3-30 03:16
Development of Combination Therapy with Targeted Agents,anded on, it is apparent that identifying new agents with novel mechanisms of activity and identifying subsets of patients who benefit from available drugs are critically important to advancing combinational approaches.作者: 根除 時(shí)間: 2025-3-30 07:35
Side Effects of Targeted Therapy,.In this chapter we describe and compare the toxicity profiles of the agents used in the treatment of mRCC and give an updated guidance on the best way to prevent and handle complications of treatment.作者: confederacy 時(shí)間: 2025-3-30 12:04
The Role of Targeted Therapy in Special Populations,clear cell histology and metastases in specific areas which may have an impact on choice of targeted therapy. Furthermore, based on the available data, we make practical recommendations on how such patients are treated in clinical practice.作者: 和諧 時(shí)間: 2025-3-30 12:26 作者: 猜忌 時(shí)間: 2025-3-30 17:35
Renal Cell Carcinoma: Pathologic and Molecular Assessment of Targets,s reason, observations are grouped according to similar features, producing a classification. Classifications can differ depending on their objective and on changes in ways of thinking over time..In cancer, the evolution of knowledge reflects the pattern observed in the general evolution of human un作者: linguistics 時(shí)間: 2025-3-30 23:20
Genomic Assessment of Renal Cancer,his chapter will focus on the most common clear cell renal cell carcinoma and the genetic origins and assessments in this disease, after a discussion of familial syndromes at risk for kidney cancers. A wide variety of platforms have been implemented to examine the DNA sequence, copy number alteratio作者: HOWL 時(shí)間: 2025-3-31 02:08
, and HIF in Clear Cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Appliction of somatic mutations, . promoter methylation and loss of heterozygosity by allele deletion. The most well-documented function of pVHL relates to its role as the substrate-recognition component of the VHL-elongin C-elongin B-cullin 2-Rbx1 E3 ubiquitin ligase complex. This complex is best known f作者: CLIFF 時(shí)間: 2025-3-31 05:33
PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex,s. It has become increasingly evident that even within specific cancer types there is incredible genetic diversity and heterogeneity, which may help explain the variability of responses to therapy. Greater understanding of these genetic changes will help the development of personalized, targeted car作者: Lament 時(shí)間: 2025-3-31 12:26
Sporadic RCC: Abnormalities in Histone-Modifying Genes,patients with metastatic disease is approximately 2 years with systemic therapy, and the most common histology is clear cell renal cell carcinoma (ccRCC). The molecular mechanism is linked to the inactivation of the von Hippel-Lindau tumor suppressor gene (.), which encodes for an oxygen sensor that作者: 使殘廢 時(shí)間: 2025-3-31 15:37
Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?,ith CCRCC. These advances in targeted therapy are fueled by a more comprehensive understanding of genetic heterogeneity in tumors that is revealing novel therapeutic targets and potentially more opportunities for individualized strategies for therapy..In CCRCC, . is the most studied genetic alterati作者: exacerbate 時(shí)間: 2025-3-31 20:12 作者: GRACE 時(shí)間: 2025-3-31 23:07 作者: RAG 時(shí)間: 2025-4-1 02:24 作者: 臆斷 時(shí)間: 2025-4-1 08:26
Anti-VEGF and VEGFR Monoclonal Antibodies in RCC,women [.]. Its management has undergone a transformation in the past few years: novel targeted therapies have expanded considerably for patients with metastatic renal cell carcinoma (mRCC). Previously, systemic treatment was limited to cytokine therapy with interleukin (IL)-2 or interferon (IFN)-alp
